SCHEMBL31534

SCHEMBL31534

Cc1nc2ccc(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)cn2c1-c1cccc(C(C)C)c1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.77
FASN P49327 1/20 0.46
ACACB O00763 2/20 0.44
ACACA Q13085 2/20 0.44
KCNK3 O14649 2/20 0.43
KCNK9 Q9NPC2 2/20 0.43
KMT2A Q03164 4/20 0.42
GRM5 P41594 2/20 0.40
SMPD3 Q9NY59 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
MEN1 O00255 2/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC2A1 P11166 3/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31533 0.89 F2RL1 (0.82) F2RL1FASNACACBACACAKCNK3
SCHEMBL15071137 0.89 F2RL1 (0.59) F2RL1KCNK3KCNK9KMT2ACNR1
SCHEMBL31519 0.87 F2RL1 (1.00) F2RL1FASNACACBACACAKCNK3
SCHEMBL15071146 0.85 F2RL1 (0.76) F2RL1FASNACACBACACAKMT2A
SCHEMBL31526 0.82 F2RL1 (0.90) F2RL1FASNACACBACACAKMT2A
SCHEMBL31560 0.77 F2RL1 (0.63) F2RL1KMT2AGRM5MEN1HPGD
SCHEMBL15071136 0.77 F2RL1 (0.62) F2RL1KMT2AMEN1HPGDTSHR
SCHEMBL15071134 0.77 F2RL1 (0.57) F2RL1KCNK3KCNK9KMT2AMEN1
SCHEMBL15071141 0.76 F2RL1 (0.61) F2RL1KMT2AGRM5MEN1HPGD
SCHEMBL15071131 0.76 F2RL1 (0.61) F2RL1KMT2AGRM5MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
WO-2012026765-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME (주)네오팜 (KR) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885FASN 2594/4885ACACB 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.